Faculty profile

Anie Philip

ResearcherSurgeryMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Anie Philip

Researcher

Surgery

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
10 publications in the last five years, latest in 2026.
Senior (last) author on 5 recent papers, a sign of leading a research group.
Principal investigator on 14 research grants (9 CIHR, 5 NSERC), most recently in 2025.
Supervised 1 trainee who won CIHR awards, most recently in 2008.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cd109 Tgf-Beta Scleroderma Alk1 Endoglin Osteoarthritis Analogues Drug Development

Latest papers

CD109 Deletion Promotes Myofibroblast Differentiation and Smad-Dependent Matrix Accumulation in Skin Fibrosis.
International journal of molecular sciences · 2026 · senior author
Correction: IL‑6‑mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL‑6 receptor‑alpha and activation of STAT3/NRF2 pathway.
Experimental hematology & oncology · 2025 · senior author
IL-6-mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL-6 receptor-alpha and activation of STAT3/NRF2 pathway.
Experimental hematology & oncology · 2025 · senior author

All 40 publications

Latest funding

Pre-clinical development of a peptide biologic for the treatment of idiopathic and scleroderma-related lung fibrosis
CIHR · 2025 · Nominated PI
$631,125
A histology platform to visualize cells, tissues and organs across living systems
NSERC · 2024 · Co-investigator
$97,880
ATARI: A Terahertz tricorder for lAseR-assIsted wound healing
NSERC · 2021 · Co-investigator
$989,500

All 20 grants and awards

40 publications.

CD109 Deletion Promotes Myofibroblast Differentiation and Smad-Dependent Matrix Accumulation in Skin Fibrosis.

Xu L, Garousi S, Batal A, Finnson KW, Philip A

International journal of molecular sciences2026Senior author

DOI: 10.3390/ijms27062834 PMID: 41898693

Correction: IL‑6‑mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL‑6 receptor‑alpha and activation of STAT3/NRF2 pathway.

Hassan A, Kungyal T, Zhou S, Blati M, Finnson K, Bertos N, Golabi N, Sadeghi N, Loganathan S, Philip A

Experimental hematology & oncology2025Senior author

DOI: 10.1186/s40164-025-00671-2 PMID: 40450341

IL-6-mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL-6 receptor-alpha and activation of STAT3/NRF2 pathway.

Hassan A, Kungyal T, Zhou S, Blati M, Finnson K, Bertos N, Golabi N, Sadeghi N, Loganathan S, Philip A

Experimental hematology & oncology2025Senior author

DOI: 10.1186/s40164-025-00630-x PMID: 40317079

CD109, a master regulator of inflammatory responses.

Batal A, Garousi S, Finnson KW, Philip A

Frontiers in immunology2024Senior author

DOI: 10.3389/fimmu.2024.1505008 PMID: 39990858

Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.

Lefrançois P, Doueidari Z, Kleiner O, Manion R, Dutz J, Philip A, Chan AW, Skin Investigation Network of Canada Priority Setting Collaborative

The British journal of dermatology2024

DOI: 10.1093/bjd/ljad387 PMID: 38114099

Top 10 research priorities for basal cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.

Shoimer I, Kleiner O, Manion R, Dutz J, Philip A, Chan AW, Skin Investigation Network of Canada Priority Setting Collaborative

The British journal of dermatology2024

DOI: 10.1093/bjd/ljad391 PMID: 38184850

Skin Investigation Network of Canada (SkIN Canada) Priority Setting Initiative ranks the top 10 evidence uncertainties for Merkel cell carcinoma.

Bergeron A, Nessim C, Kleiner O, Manion R, Dutz J, Philip A, Chan AW, Skin Investigation Network of Canada Priority Setting Collaborative

The British journal of dermatology2024

DOI: 10.1093/bjd/ljad398 PMID: 37864824

Top Ten Research Priorities for Psoriasis, Atopic Dermatitis and Hidradenitis Suppurativa: The SkIN Canada Priority Setting Initiative.

Drucker AM, Kleiner O, Manion R, Philip A, Dutz J, Barnard K, Fradette J, Germain L, Gniadecki R, Litvinov I, Logsetty S, Manolson M, Mydlarski PR, Piguet V, Ward D, Zhou Y, Chan AW, Skin Investigation Network of Canada Priority Setting Collaborative

Journal of cutaneous medicine and surgery2023

DOI: 10.1177/12034754231156103 PMID: 36995350

Informing a Canadian Skin Science Trainee Program Based on the State of Trainee Programs Offered by International Academic Societies.

Brooks SG, Pawluk MA, Litvinov IV, Fradette J, Chan AW, Philip A, Croitoru D, Richardson KC

Journal of cutaneous medicine and surgery2023

DOI: 10.1177/12034754221137570 PMID: 36408849

CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells.

Zhou S, Hassan A, Kungyal T, Tabariès S, Luna JLRG, Siegel PM, Philip A

Cancers2022Senior author

DOI: 10.3390/cancers14153672 PMID: 35954339

Pre-clinical development of a peptide biologic for the treatment of idiopathic and scleroderma-related lung fibrosis

Nominated PICIHR2025Project Grant

Principal investigators: Philip, Anie

Keywords: Analogues; Drug Development; Fibroblasts; Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Peptides; Pharmacokinetics; Safety And Toxicity Studies; Scleroderma; Transforming Growth Factor-Beta

$631,125

A histology platform to visualize cells, tissues and organs across living systems

Co-investigatorNSERC2024Research Tools and Instruments

Principal investigators: Cockburn, Katherine

Keywords: Animal models; Biomedical engineering; Cell biology; Cell morphology; Gene expression; Histology; Materials science; Tissue architecture; Tissue sectioning

$97,880

ATARI: A Terahertz tricorder for lAseR-assIsted wound healing

Co-investigatorNSERC2021Alliance Grants

Principal investigators: Naccache, Rafik

$989,500

Role of endoglin in the regulation of extracellular matrix dynamics in the skin

Principal investigatorNSERC2021Discovery Grants Program - Individual

Principal investigators: Philip, Anie

$128,000

TARANTULA: TerAheRtz-Assisted Nanoparticle Therapeutics Using LAsers

Co-investigatorSSHRC2020New Frontiers in Research Fund - Exploration

Principal investigators: Castonguay, Annie

$250,000

Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma

Nominated PICIHR2020Project Grant

Principal investigators: Philip, Anie; Leask, Andrew C

Keywords: Cd109; Fibrosis; Peptide; Scleroderma; Tgf-Beta

$810,900

Role of CD109 in regulating cellular signaling and responses in skin and oral squamous cell carcinoma cells

Nominated PICIHR2018Project Grant

Principal investigators: Philip, Anie

Keywords: Cd109; Cell Signaling; Epidermal Growth Factor; Jak/Stat3; Metastasis; Squamous Cell Carcinoma; Tgf-Beta

$1,074,825

Canadian Scleroderma Research Group Meeting: Training and standardization of biospecimen collection and biobanking protocols for Scleroderma Research in Canada

Co-investigatorCIHR2017Planning and Dissemination Grant - Institute Community Support

Principal investigators: Baron, Murray

Keywords: Biospecimens; Scleroderma; Skin Biopsy; Systemic Sclerosis

$9,498

Regulation of TGF-beta action in chondrocytes: signaling via ALK1 versus ALK5 pathways

Nominated PICIHR2016Project Grant

Principal investigators: Philip, Anie

Keywords: Alk1; Alk5; Cartilage; Cd109; Endoglin; Osteoarthritis; Tgf-Beta

$630,715

Regulation of TGF-beta action in chondrocytes: signaling via ALK1 versus ALK5 pathways

Nominated PICIHR2015Operating Grant

Principal investigators: Philip, Anie

Keywords: Alk1; Animal Models; Cd109; Endoglin; Osteoarthritis; Tgf-Beta

$100,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Anie Philip

Research

Latest papers

Latest funding

CD109 Deletion Promotes Myofibroblast Differentiation and Smad-Dependent Matrix Accumulation in Skin Fibrosis.

Correction: IL&#x2011;6&#x2011;mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL&#x2011;6 receptor&#x2011;alpha and activation of STAT3/NRF2 pathway.

IL-6-mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL-6 receptor-alpha and activation of STAT3/NRF2 pathway.

CD109, a master regulator of inflammatory responses.

Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.

Top 10 research priorities for basal cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative.

Skin Investigation Network of Canada (SkIN&#xa0;Canada) Priority Setting Initiative ranks the top 10 evidence uncertainties for Merkel cell carcinoma.

Top Ten Research Priorities for Psoriasis, Atopic Dermatitis and Hidradenitis Suppurativa: The SkIN Canada Priority Setting Initiative.

Informing a Canadian Skin Science Trainee Program Based on the State of Trainee Programs Offered by International Academic Societies.

CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells.

Pre-clinical development of a peptide biologic for the treatment of idiopathic and scleroderma-related lung fibrosis

A histology platform to visualize cells, tissues and organs across living systems

ATARI: A Terahertz tricorder for lAseR-assIsted wound healing

Role of endoglin in the regulation of extracellular matrix dynamics in the skin

TARANTULA: TerAheRtz-Assisted Nanoparticle Therapeutics Using LAsers

Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma

Role of CD109 in regulating cellular signaling and responses in skin and oral squamous cell carcinoma cells

Canadian Scleroderma Research Group Meeting: Training and standardization of biospecimen collection and biobanking protocols for Scleroderma Research in Canada

Regulation of TGF-beta action in chondrocytes: signaling via ALK1 versus ALK5 pathways

Regulation of TGF-beta action in chondrocytes: signaling via ALK1 versus ALK5 pathways

Frequent collaborators

An-Wen Chan

Satya Prakash

Rachael Manion

Jan Dutz

Satya Prakash

Julie Fradette

Jan Dutz

SAMPATH Loganathan

Nader Sadeghi

Anie Philip

Stéphane Roy

Morag Park

Robert Gniadecki

Ivan Litvinov

Sarvesh Logsetty

Morag Park

Robert Platt

Dusica Maysinger

Mohit Kapoor

Mohit Kapoor

Vincent Piguet

Andrew Leask

Donald Poirier

Youwen Zhou

Lucie Germain

Vincent Giguere

Mohit Kapoor

Murray Baron

Morris Manolson

Correction: IL‑6‑mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL‑6 receptor‑alpha and activation of STAT3/NRF2 pathway.

Skin Investigation Network of Canada (SkIN Canada) Priority Setting Initiative ranks the top 10 evidence uncertainties for Merkel cell carcinoma.